Open AccessBudesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease
Author(s) -
Douglas W. Mapel,
Melissa H. Roberts,
Jill Davis
Publication year - 2020
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2019-0161
Subject(s) - medicine , budesonide , formoterol , salmeterol , budesonide/formoterol , asthma , inhaler , exacerbation , copd , pulmonary disease , fluticasone , fluticasone propionate , intensive care medicine , asthma exacerbations , physical therapy
Aim: Quality, real-world comparative effectiveness (CE) studies of asthma and chronic obstructive pulmonary disease therapy efficacy are scarce. We identified and evaluated peer-reviewed CE and appropriate-use evaluations of budesonide/formoterol combination (BFC) maintenance therapy. Materials & methods: Analyses were limited to retrospective, real-world utilization studies of BFC delivered by pressurized metered-dose inhalers. Results: In a CE study of BFC versus fluticasone/salmeterol combinations (FSC) in asthma, BFC users had fewer total exacerbations. In appropriate-use studies of asthma treatment, BFC patients were consistently more likely to meet treatment escalation recommendations. BFC comparisons with FSC or tiotropium for chronic obstructive pulmonary disease found differences in exacerbation rates and rescue inhaler use. Conclusion: We found available, good quality BFC CE and appropriate-use articles; however, all had limitations.